Form 4: AVNS CFO Awarded Equity and Stock Options

AVANOS MEDICAL, INC.'s SVP and CFO, Scott Michael Galovan, received significant equity awards and stock options as part of the company's long-term incentive plan.

Summary

• Scott Michael Galovan, SVP, Chief Financial Officer of AVANOS MEDICAL, INC. (AVNS), was awarded 29,481 time-based restricted share units (TRSUs) on March 13, 2026, under the Issuer's 2021 Long Term Incentive Plan.
• These TRSUs will vest in three tranches: one-third on March 13, 2027, one-third on March 13, 2028, and one-third on March 13, 2029.
• Following this transaction, Mr. Galovan beneficially owns 139,824 shares of Common Stock.
• Additionally, Mr. Galovan was granted 69,630 employee stock options with an exercise price of $13.69 per share on March 13, 2026, expiring on March 13, 2036.
• These stock options will vest as follows: 30% on March 13, 2027, 30% on March 13, 2028, and 40% on March 13, 2029.
• After this grant, Mr. Galovan beneficially owns 96,212 derivative securities (employee stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the enhanced alignment of executive incentives with shareholder interests and the reinforcement of executive retention. It is a routine compensation disclosure rather than a direct indicator of operational performance.

Positives

• The equity awards and stock options align the interests of the Chief Financial Officer with those of shareholders, incentivizing long-term company performance.
• The multi-year vesting schedule for both TRSUs and stock options serves as a strong retention mechanism for key executive talent.
• The awards are part of a structured long-term incentive plan, indicating a commitment to executive performance and shareholder value creation.

Negatives

• The awards do not provide immediate liquidity or cash benefits to the officer, as they are subject to vesting schedules.
• The value of the awards is tied to the future performance of AVANOS MEDICAL, INC.'s stock, introducing market risk for the recipient.

Risks

• The ultimate value of the awarded restricted share units and stock options is subject to the future market price fluctuations of AVANOS MEDICAL, INC. common stock.
• The vesting schedules mean the awards are not immediately realized and depend on continued employment and company performance over several years.

Future Outlook

The awards are part of the Issuer's 2021 Long Term Incentive Plan, indicating a strategic focus on aligning executive compensation with future company performance and shareholder value creation over a multi-year horizon.

Industry Context

StockSavvy.ai notes that the granting of time-based restricted share units and stock options to senior executives is a common and widely accepted practice within the medical device industry. This approach is designed to align management's financial incentives with the long-term performance of the company and to ensure executive retention in a competitive talent market.

Comparison to Industry Standards

• Equity-based compensation, including restricted stock units and stock options with multi-year vesting schedules, is a standard component of executive compensation packages across the healthcare and medical technology sectors.
• Companies like Medtronic, Johnson & Johnson, and Stryker frequently utilize similar long-term incentive structures to motivate and retain their leadership teams, linking executive wealth creation directly to shareholder returns.

Stakeholder Impact

• Shareholders: The awards aim to align the Chief Financial Officer's financial interests with long-term shareholder value, potentially leading to more focused strategic decisions.
• Employees (specifically the CFO): The awards provide significant long-term compensation potential, contingent on company performance and continued employment, enhancing retention.

Next Steps

• The restricted share units and stock options will vest according to their specified schedules on March 13, 2027, March 13, 2028, and March 13, 2029.

Key Dates

Recommendation

This Form 4 reports routine executive equity compensation, which is a standard practice for aligning management incentives with shareholder interests. It does not provide new information on company performance, strategic direction, or material financial changes that would warrant a change in investment recommendation. Investors should consider this as a normal course of business for executive compensation.

Keywords

AVANOS MEDICAL, AVNS, Scott Michael Galovan, Form 4, Insider Transaction, Equity Award, Stock Options, Restricted Share Units, CFO Compensation, Long Term Incentive Plan, Executive Compensation